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Introduction: This study aimed to determine the efficacy of different Leucovorin regimens to reduce oral mu-
cositis in children with acute lymphoblastic leukemia after high-dose Methotrexate (HD-MTX).
Methods: Twelve articles were included in a systematic literature review. Articles were categorized into low/
medium/high risk of bias.
Results: As no randomized controlled trial assessing the effect of Leucovorin has been performed, the efficacy of
Leucovorin to reduce oral mucositis remains unknown. Leucovorin was initiated at 24, 36 or 42 h after HD-MTX
at a dose of 15 or 30mg/m2. No meta-analysis could be performed as treatment regimens differed. When
comparing studies with similar HD-MTX doses, we observed lower oral mucositis rates in regimens with higher
cumulative doses of Leucovorin and early initiation of Leucovorin after MTX.
Conclusion: Even though future studies are necessary, higher cumulative Leucovorin doses and early initiation of
Leucovorin after start of MTX seem to reduce oral mucositis.
1. Introduction
Over the past decades, five-year survival rates of children with acute
lymphoblastic leukemia (ALL) have reached 90% in the developed
countries (Hunger et al., 2012; Pui et al., 2011; Kamps et al., 2010).
However, patients often suffer from toxicity of chemotherapeutic drugs
such as Methotrexate (MTX) (den Hoed et al., 2015; Pieters et al.,
2016).
MTX is an antifolate drug that depletes intracellular reduced folate
levels by inhibiting the enzymes Thymidylate Synthase and
Dihydrofolate Reductase. This depletion of intracellular reduced folate
levels impairs DNA- and RNA-synthesis leading to cell death in cells
with a high cell turnover, such as in the bone marrow and in the gastro-
intestinal tract including the oral mucosa (Funk et al., 2014; Kao et al.,
2013; Bostrom et al., 2003). In addition, MTX was shown to alter the
diversity and principal components of oral and gut microbiota, thereby
affecting the inflammatory response associated with damage to the
mucosal epithelium (Zhang et al., 2015; Zhou et al., 2018). These
changes in the composition of microbiota in response to MTX were
associated with developing MTX-induced mucositis in mice studies and
in rheumathoid arthritis patients (Zhang et al., 2015; Zhou et al., 2018).
After HD-MTX infusions, folinic acid rescue therapy (Leucovorin – LV)
is administered to reduce toxic side effects (Wennerstrand et al., 2013;
Cohen and Wolff, 2014). LV is a reduced folate that bypasses the block
of DHFR by MTX (Relling et al., 1994; Wolfrom et al., 1993; Goldie
et al., 1975). The administration of LV is therefore thought to decrease
toxic side effects by “rescuing” cells from MTX-induced cell death
(Relling et al., 1994; Wolfrom et al., 1993; Goldie et al., 1975). We
previously showed that severe (grade III/IV) MTX-induced oral muco-
sitis occurs in 20% of patients in a prospective study of children with
ALL despite adequate LV rescue therapy (den Hoed et al., 2015). Severe
MTX-induced oral mucositis causes an impairment of the quality of life
of children and can lead to treatment delays (den Hoed et al., 2015;
Shimasaki et al., 2006; Liu et al., 2011).
HD-MTX and additional LV rescue therapy protocols differ between
countries. The introduction of LV rescue therapy has been established
entirely empirically throughout the past decades and, even today, the
basis for the “effectivity” to reduce oral mucositis rates and the
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“selectivity” of this regimen is not widely appreciated nor fully un-
derstood (Relling et al., 1994; Borsi et al., 1991). Furthermore, it has
been suggested that plasma and intracellular folate status before the
start of HD-MTX and LV therapy may affect oral mucositis rates (den
Hoed et al., 2015; Robien, 2005).
The present review was conducted to determine the effectivity of
various Leucovorin dosing- and timing regimens to reduce oral muco-
sitis and to determine the role of pre-treatment plasma- and in-
tracellular folate levels in the development of MTX-induced oral mu-
cositis.
2. Methods
2.1. Literature search strategy
A literature search was performed on June 18th 2018 in Pubmed,
Embase and Cochrane. A systematic search was developed with the
following main search terms: Leucovorin / Folate rescue therapy AND
Methotrexate AND Acute Lymphoblastic Leukemia (Supplemental
Table 1). As ‘oral mucositis’ was often not mentioned in the title /
abstract, we first included all articles in which it seemed that data on
toxicity would be available in the full-text and only identified articles
with data on ‘oral mucositis’ after full-text screening.
2.2. Inclusion and exclusion criteria
To be eligible for inclusion, a study had to include (Hunger et al.,
2012) children aged ≤21 years with acute lymphoblastic leukemia or
lymphoma (including studies on children with Down Syndrome) (Pui
et al., 2011), high-dose methotrexate treatment (≥1 g/m2) (Kamps
et al., 2010), data on LV or folinic acid rescue therapy including dosing
and / or timing (den Hoed et al., 2015), incidence/prevalence data on
oral mucositis. Furthermore, studies that contained data on (Pieters
et al., 2016) folate plasma- or erythrocyte folate levels in relation to the
development of oral mucositis were included. Animal or cell-line stu-
dies, case reports, expert opinions, reviews, conference abstracts, arti-
cles in languages other than English or Dutch and studies without a full
text available were excluded.
2.3. Data extraction and analysis
After removal of duplicates, 659 studies remained (Fig. 1). After
title/abstract selection by two independent reviewers (JNvdB, NO), the
remaining 85 articles were assessed full text. In total, 12 studies were
identified to be relevant based on the defined aims and inclusion cri-
teria.
2.4. Data search
The following data were extracted from the included studies: author
and year of publication; country; study design; number of patients in-
cluding median age; protocol; methotrexate dosing and/or timing;
leucovorin dosing and / or timing; folate (plasma / intracellular) levels;
system used for toxicity screening; prevalence and/or severity of mu-
cositis, focused mainly on ‘clinically relevant’ mucositis. Oral mucositis
grade ≥3 according to either the National Cancer Institute Common
Toxicity Criteria (NCI-CTC) or the World Health Organization (WHO)
toxicity grading scale was defined as clinically relevant mucositis in this
study. In the NCI-CTC scale oral mucositis grade 3 was defined as
“severe pain, interfering with oral intake” (CTCAE, 2006; WHO, 2003).
In the WHO toxicity grading scale oral mucositis grade 3 was defined as
“painful and the inability to swallow solids” (WHO, 2003).
2.5. Quality of evidence assessment
The quality of the included studies was determined by assessing the
level of bias using the Quality in Prognosis Studies (QUIPS) tool
(Hayden et al., 2013). The studies were reviewed for the six domains:
study participation, study attrition, prognostic factor measurement,
outcome measurement, study confounding and statistical analysis /
reporting. The quality of evidence was categorized into 3 levels, being
‘high risk of bias’, ‘moderate risk of bias’ and ‘low risk of bias’. Ac-
cording to the recommendation of Hayden et al., we chose a priori
domains out of the six domains most relevant for this review to de-
termine a sum score (Hayden et al., 2013). Study participation, prog-
nostic factor measurement and outcome measurement, were used as a
priori domains.
3. Results
Studies were published between 1983 and 2018 and included be-
tween 12 and 485 study participants. In total, 4 studies were retro-
spective cohort studies, 6 were prospective cohort studies and 2 were
randomized controlled trials that compared two doses of HD-MTX. The
included studies described patients receiving HD-MTX doses ranging
between 1 g/m2/dose and 12 g/m2/dose, in which 1 g/m2/dose (2
studies), 3 g/m2/dose (3 studies) and 5 g/m2/dose (3 studies) were the
most common doses. The prevalence of oral mucositis NCI-CTC/WHO
grade ≥3, ranged between 0% and 41%. Albertioni et al reported a
percentage of 44%, with a cut-off value of WHO grade ≥1 (Albertioni
et al., 1997). None of these studies compared the outcome of patients
with and without LV rescue therapy in a randomized setting and we
could therefore not determine the effect of LV rescue therapy on re-
ducing the oral mucositis rate.
3.1. The effect of leucovorin dosing on HD-MTX induced oral mucositis
Twelve studies on the effect of dosing of LV rescue therapy were
included in our study (Table 1), of which 4 had a ‘low risk of bias’ and 8
had a ‘medium risk of bias’ (Supplemental Table 2) (den Hoed et al.,
2015; Relling et al., 1994; Wolfrom et al., 1993; Albertioni et al., 1997;
Zhang et al., 2014; Pauley et al., 2013; Vaishnavi et al., 2018; Gemma
et al., 2017; Moulik et al., 2016; Kapoor et al., 2012; Xu et al., 2007;
Frankel et al., 1983). The starting doses of LV rescue therapy ranged
between 10mg/m2/dose and 30mg/m2/dose, of which 15mg/m2 and
30mg/m2 were used most commonly. The cumulative doses of LV
rescue therapy ranged between 30mg/m2 and 90mg/m2. Out of twelve
included studies, two studies described the use of locally administered
topical doses of LV to the oral mucosa during HD-MTX in addition to
the LV administered orally or intravenously. It was not possible to de-
termine the effect of locally administered topical doses of LV to the oral
mucosa on the oral mucositis rate as these two studies did not rando-
mize patients into patients with and without the topical administered
doses (Albertioni et al., 1997; Xu et al., 2007).
We were able to compare data on the cumulative doses of LV ad-
ministered in relation to developing MTX-induced oral mucositis in five
out of twelve included studies (Fig. 2) (den Hoed et al., 2015; Wolfrom
et al., 1993; Moulik et al., 2016; Kapoor et al., 2012; Frankel et al.,
1983). Seven studies were excluded from this analysis as they either
used individualized MTX-dosing, lacked a specified LV rescue therapy
regimen or MTX regimen in which the cumulative dose per therapy
group could not be calculated, lacked a grading system for toxicity or
had a cut-off for toxicity other than grade ≥3 (Relling et al., 1994;
Albertioni et al., 1997; Zhang et al., 2014; Pauley et al., 2013;
Vaishnavi et al., 2018; Gemma et al., 2017; Xu et al., 2007).
Two out of five studies administered 1 g/m2/dose MTX in either
36 h followed by a cumulative LV dose of 30mg/m2 or in 1 h followed
by a cumulative LV dose of 45mg/m2, resulting in an oral mucositis
rate of 41% and 12% respectively (Fig. 2) (Wolfrom et al., 1993;
Frankel et al., 1983). In these studies, we observed a lower rate of oral
mucositis when HD-MTX was infused in a short period with higher
cumulative LV doses (Frankel et al., 1983), than when HD-MTX was
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infused in a longer period with lower cumulative LV doses (Wolfrom
et al., 1993).
One out of five studies administered 3 g/m2/dose MTX in an un-
known infusion period followed by a cumulative LV dose of 90mg/m2,
resulting in an oral mucositis rate of 29% (Fig. 2) (Moulik et al., 2016).
Two out of five studies administered 5 g/m2/dose MTX in 24 h
followed by either a cumulative LV dose of 45mg/m2 or 90mg/m2,
resulting in an oral mucositis rate of 20% and 5% respectively (Fig. 2)
(den Hoed et al., 2015; Kapoor et al., 2012). In these two studies, we
observed a decreased rate of oral mucositis when higher LV doses were
administered (Kapoor et al., 2012).
This Figure shows the percentage of oral mucositis per HD-MTX
dose and cumulative LV dose per study
3.2. The effect of leucovorin timing on HD-MTX induced oral mucositis
Twelve studies on the timing of LV rescue therapy after start of HD-
MTX were included in our study (Table 1), of which 4 had a ‘low risk of
bias’, 7 had a ‘medium risk of bias’ and 1 had a ‘high risk of bias’
(Supplemental Table 2) (den Hoed et al., 2015; Relling et al., 1994;
Wolfrom et al., 1993; Albertioni et al., 1997; Zhang et al., 2014; Pauley
et al., 2013; Vaishnavi et al., 2018; Gemma et al., 2017; Moulik et al.,
2016; Kapoor et al., 2012; Xu et al., 2007; Frankel et al., 1983). Most
studies started their LV rescue therapy at 24 h, 36 h or 42 h after in-
itiation of HD-MTX (den Hoed et al., 2015; Relling et al., 1994;
Wolfrom et al., 1993; Albertioni et al., 1997; Zhang et al., 2014; Pauley
et al., 2013; Vaishnavi et al., 2018; Gemma et al., 2017; Moulik et al.,
2016; Kapoor et al., 2012; Xu et al., 2007). We were able to compare
data on the timing of LV in relation to developing MTX-induced oral
mucositis in six out of twelve included studies as previously mentioned
(Fig. 3) (den Hoed et al., 2015; Wolfrom et al., 1993; Moulik et al.,
2016; Frankel et al., 1983).
Two out of six studies administered 1 g/m2/dose MTX in either 36 h
followed by LV starting at 24 h or in 1 h followed by LV dose starting at
6 h, resulting in an oral mucositis rate of 41% and 12% respectively
(Wolfrom et al., 1993; Frankel et al., 1983). Another two studies ad-
ministered 5 g/m2/dose MTX in 24 h followed by LV starting at 42 h,
resulting in an oral mucositis rate of 20% and 5% respectively (den
Hoed et al., 2015; Kapoor et al., 2012). One study randomized patients
to receiving 5 g/m2/dose MTX in either 7 or 24 h followed by LV
starting at 36 h, resulting in an oral mucositis rate of 0% (Xu et al.,
2007). Overall, we observed an increase of the oral mucositis rate when
the timing of LV administration after initiation of MTX was delayed in
the 1 g/m2/dose- and 5 g/m2/dose MTX-studies (Fig. 3).
In the two studies, in which 3 g/m2/dose MTX followed by LV
starting at either 24 h or 36 h was administered, the opposite effect was
observed showing lower mucositis rates when LV initiation was delayed
(Fig. 3) (Moulik et al., 2016; Xu et al., 2007). One factor that might
explain that the opposite effect was observed in the studies of Moulik
et al. and Xu et al. could be that in addition to normal LV administration
also topical LV was administered to the oral mucosa in the study of Xu
et al. to reduce oral mucositis (Moulik et al., 2016; Xu et al., 2007).
This Figure shows the percentage of oral mucositis per HD-MTX
dose and LV timing (number of hours after start of HD-MTX infusion)
per study.
3.3. Plasma- and erythrocyte folate levels
Two out of twelve included studies provided data on the association
between baseline plasma- and intracellular folate and the development
Fig. 1. Flowchart literature study.
Flowchart of literature search and number of included studies.
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of MTX-induced oral mucositis (Table 2), of which 1 had a ‘low risk of
bias’ and 1 had a ‘medium risk of bias’ (Appendix 2) (den Hoed et al.,
2015; Moulik et al., 2016). We previously showed that patients with
oral mucositis had a significantly higher level of baseline erythrocyte
folate compared to patients without oral mucositis, whereas plasma
folate was not associated to oral mucositis. We showed that when the
erythrocyte folate concentration increased with 1 μmol/l, the odds of
developing oral mucositis were 1.23 (95% confidence interval (CI)
1.04–1.45) (den Hoed et al., 2015). Moulik et al. examined a small
group of patients in whom a plasma folate deficient state was not as-
sociated with oral mucositis (Moulik et al., 2016). Erythrocyte folate
levels were not measured in this study (Moulik et al., 2016).
3.4. Other findings on the prevalence of HD-MTX induced oral mucositis
First, when comparing the oral mucositis rate between studies using
different HD-MTX doses, the overall rate of oral mucositis seemed to be
lower in the studies using 5 g/m2/dose HD-MTX compared to the stu-
dies using lower HD-MTX doses. This result was also reported in two
randomized clinical trials comparing 3 versus 5mg/m2/dose MTX and
1 versus 12mg/m2/dose MTX respectively (Wolfrom et al., 1993; Xu
et al., 2007). However, in the study of Wolfrom et al. this difference
could be explained by a longer infusion period of 36 h in the 1 g/m2
MTX versus only 4 h in the 12 g/m2 MTX and a more intensive LV
rescue therapy regimen in the 12 g/m2 MTX dose, which included both
higher cumulative doses of LV and a more early timing of LV (Wolfrom
et al., 1993). In the study of Xu et al. this difference could be explained
by more intensive pre-hydration measures and higher cumulative LV
doses in the 5 g/m2 MTX group versus the 3 g/m2 MTX group. This
finding of a lower oral mucositis rate in patients receiving higher doses
of MTX could thus be explained by either a longer MTX infusion period
or a more intensive LV regimen (Xu et al., 2007).
Second, when comparing the oral mucositis rate in recent studies
compared to older studies, we observed less oral mucositis in the more
Fig. 2. Prevalence of mucositis grade ≥3 for
cumulative LV doses per cycle per HD-MTX
dose.
= High risk of bias; = Moderate risk of bias;
= Low risk of bias.
Fig. 3. Prevalence of mucositis grade ≥3 for
timing of first administration of LV after in-
itiation of MTX per cycle per HD-MTX dose.
= High risk of bias; = Moderate risk of bias;
= Low risk of bias.
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recent studies, published since 2007 (range 0–29%), compared to the
older studies (range 12–41%) (Table 1).
Third, two studies described the use of individualized MTX and LV
dosing based on MTX plasma levels and pharmacokinetic models
(Relling et al., 1994; Pauley et al., 2013). Pauley et al. compared in-
dividualized MTX and LV dosing compared to standardized MTX and LV
treatment and observed lower oral mucositis rates (low risk therapy
group: 7% - standard/high risk group: 8%) in the individualized
therapy group compared to the rates in the standardized therapy group
(low risk therapy group: 9% - high risk therapy group: 13%) (Pauley
et al., 2013).
Finally, two studies reported that the rate of MTX-induced oral
mucositis was higher after the first cycle of MTX (den Hoed et al., 2015;
Kapoor et al., 2012). Den Hoed et al. showed a prevalence of NCI-CTC
(v.3.0) grade ≥3 mucositis of 15% in the first cycle compared to a
prevalence of 8% in the remaining three HD-MTX courses (den Hoed
et al., 2015). Kapoor et al. showed a prevalence of NCI-CTC (v.3.0)
grade ≥3 mucositis of 12% in the first cycle compared to a prevalence
of 3%, 6% and 0% in cycle 2, 3 and 4 respectively (Kapoor et al., 2012).
4. Discussion
The present systematic review was conducted to determine the ef-
fect of LV rescue therapy on developing oral mucositis during HD-MTX
treatment in pediatric ALL. This is the first systematic review to sum-
marize knowledge on different LV regimens in relation to the oral
mucositis rate. We could not perform a meta-analysis of results as
treatment regimens differ throughout the world. However, when com-
paring studies with similar HD-MTX doses, we observed lower muco-
sitis rates in therapy regimens with higher cumulative doses of LV and
early initiation of LV after MTX.
Overall, the percentage of MTX-induced oral mucositis seemed to
decrease when the LV dose increased. This could be explained by the
hypothesis that LV (folinic acid) bypasses Dihydrofolate Reductase and
restores the cellular folate pool after HD-MTX therapy and thereby
decreases toxic side effects in a dose – response relation (Relling et al.,
1994; Wolfrom et al., 1993; Goldie et al., 1975). By initiating LV earlier
after HD-MTX therapy, it is thought that the sooner the cellular folate
pool is restored after HD-MTX in normal cells, the less toxicity occurs.
These results held even when MTX doses were higher and when the
MTX infusion period was shorter.
Several studies reported a higher prevalence of oral mucositis in the
first cycle compared to the following cycles of HD-MTX. One explana-
tion might lie in the previously proposed ‘folate overrescue’ concept
(Cohen and Wolff, 2014; Borsi et al., 1991; Zhang et al., 2014). This
concept is based on the fact that LV and MTX are structural analogues
and might compete for the same cellular transport mechanisms and / or
act antagonistically inside the cell during subsequent HD-MTX and LV
courses (den Hoed et al., 2015; Skarby et al., 2006). This would lead to
a reduction in toxicity rates during subsequent HD-MTX and LV courses.
However, this raises the important question if rescue therapy with LV
may compromise the effect of MTX by ‘rescuing’ malignant cells from
the effect of HD-MTX and may induce more relapses. Studies on this
‘folate overrescue’ concept show inconsistent and contradictory results
(Cohen and Wolff, 2014; Skarby et al., 2006; Sterba et al., 2005; Cohen,
2004; Takacs and Rodriguez, 2005; Valik et al., 2005). Another ex-
planation for reduced toxicity over time during consecutive MTX doses
might be that in pre-clinical studies a downregulation in the Reduced
Folate Carrier 1 has been shown in response to an initial dose of MTX
(Ma et al., 2000). It is clinically important that these two perspectives
are taken into account in future studies on how LV doses and timing
should be optimized to reduce the oral mucositis rate, as the anti-leu-
kemic effectivity of HD-MTX therapy should not be compromised.
In this review we included two studies on the effect of baseline
plasma and intracellular erythrocyte folate levels in relation to the
development of MTX-induced oral mucositis (den Hoed et al., 2015;Ta
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Moulik et al., 2016). In literature, two hypotheses exist on plasma and
intracellular folate levels in relation to developing HD-MTX toxicity.
First, studies have suggested that baseline intracellular folate levels are
a reflection of the cell’s capacity to transport and retain cellular folates
/ MTX. This would suggest that the higher the intracellular level of
folate at baseline, the higher subsequent intracellular MTX levels and
the higher the oral mucositis rate (de Rotte et al., 2013; Kim et al.,
1998). This is supported by our earlier study, even though the effect
size of this study was small (den Hoed et al., 2015). Furthermore,
several rheumatoid arthritis studies support this hypothesis (den Hoed
et al., 2015; Dervieux et al., 2005). In contrast, studies have suggested
that a low level of intracellular folate at baseline predisposes to in-
creased HD-MTX toxicity rates as more MTX is able to enter the cell due
to low competition for the same transport mechanisms (Robien, 2005;
Moulik et al., 2016; Lopez-Lopez et al., 2013). This poses the question
whether pre-treatment folate supplementation would reduce oral mu-
cositis rates in HD-MTX therapy (Cohen and Wolff, 2014). More re-
search to elucidate the exact role of baseline folate levels in relation to
developing oral mucositis is necessary. Future studies could then focus
on personalizing LV to the individual need of a patient.
Out of the twelve studies in our systematic review on the effect of
LV rescue therapy on MTX-induced oral mucositis, the majority of
studies were classified as having a ‘moderate risk of bias’. No rando-
mized controlled trial in which patients with and without LV rescue
therapy were compared has been performed. Therefore, the exact effect
of LV rescue therapy on reducing the oral mucositis rate remains un-
known. As dosing and timing of LV were never studied separately and
none of the studies was designed specifically to answer whether LV
dosing or timing affected oral mucositis rates, we cannot fully distin-
guish between the effect of dosing and of timing of LV on reducing oral
mucositis and results should be interpreted as such. In addition, many
studies did not specify other relevant supportive care measures that
might affect toxicity rates, such as hyperhydration or urine alkalinisa-
tion. Finally, the oral mucositis rate was often based on a retrospective
study of toxicities and different types of grading systems, which might
influence comparison of numbers between studies. We aimed to de-
crease the interindividual differences in reporting by only including
severe grade ≥ 3 oral mucositis, which requires medical intervention
and is thought to be less underreported. Nevertheless, these important
factors should be taken into account in future studies into the dosing or
timing of LV to reduce toxicity.
In conclusion, when comparing studies with similar treatment
characteristics we observed less oral mucositis in HD-MTX and LV re-
gimens in which higher cumulative doses of LV were administered and
when LV was initiated early after HD-MTX, but more studies designed
specifically to determine the most optimal dosing and timing of LV are
necessary to confirm this. The effect of baseline folate levels on the
development of MTX-induced oral mucositis remains unclear.
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